Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 18/20 | 0.67 |
| ▸ | GSK3B | P49841 | 16/20 | 0.67 |
| ▸ | AURKB | Q96GD4 | 13/20 | 0.67 |
| ▸ | SRC | P12931 | 9/20 | 0.67 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18166026 | 0.89 | AURKA (0.62) | AURKAGSK3BAURKBSRCAURKC | |
| SCHEMBL29487420 | 0.89 | AURKA (0.62) | AURKAGSK3BAURKBSRCAURKC | |
| SCHEMBL18154839 | 0.84 | AURKB (0.68) | AURKAGSK3BAURKBSRCAURKC | |
| SCHEMBL29487425 | 0.81 | AURKA (0.51) | AURKAGSK3BAURKBSRCAURKC | |
| SCHEMBL19998181 | 0.81 | AURKA (0.51) | AURKAGSK3BAURKBSRCAURKC | |
| SCHEMBL12430446 | 0.80 | AURKA (1.00) | AURKAGSK3BAURKBSRCAURKC | |
| SCHEMBL18154841 | 0.80 | AURKB (0.70) | AURKAGSK3BAURKBSRCAURKC | |
| SCHEMBL18166041 | 0.80 | AURKA (0.50) | AURKAGSK3BAURKBSRCAURKC | |
| SCHEMBL29487455 | 0.80 | AURKA (0.50) | AURKAGSK3BAURKBSRCAURKC | |
| SCHEMBL19990856 | 0.79 | AURKB (0.66) | AURKAGSK3BAURKBSRCAURKC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200383990-A1 | METHODS OF TREATING CANCER WITH PLK4 INHIBITORS | LUDWI INSTITUTE FOR CANCER RESEARCH LTD. (CH) | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383990-A1 | METHODS OF TREATING CANCER WITH PLK4 INHIBITORS | PLK4, PLK2, PLK3 | AURKA 71/4885GSK3B 154/4885AURKB 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.